Madrigal Expands Rezdiffra Patent Portfolio Into 2045
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has secured three new U.S. patents for its liver disease drug Rezdiffra, extending intellectual property protection for key treatment methods through as …
Madrigal Expands Rezdiffra Patent Portfolio Into 2045 Read More